PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

  • End date
    Dec 31, 2025
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 29 January 2021


This study aims to explore the role of PD-1 Antibody in preventing adenomatous polyps and second primary tumors in patients with Lynch Syndrome. There two arms, one is the experimental arm (PD-1 antibody prevention group) and the other is the control arm (routine follow-up group). For the experimental group, Tripleitriumab (PD-1 antibody) is given every 3 months for a year.


Lynch syndrome (LS) is a hereditary cancer syndrome that causes the majority of hereditary CRC and approximately 3% of all CRC. LS significantly increases the risk for an individual to develop CRC during their lifetime. Individuals with LS also have an increased risk to develop extracolonic cancers, including endometrial, gastric, ovarian, upper urinary tract, small bowel, biliary tract, CNS, and certain types of skin cancer. Given the hereditary nature of this syndrome, preventing second primary tumors in patients with Lynch Syndrome after surgery to the primary site is very important.

The purpose of this study is to prevent adenomatous polyps and second primary tumors using PD-1 antibody (Tripleitriumab) in patients with Lynch Syndrome.

The primary outcome of this study is the incidence of intestinal adenomatous polyps and secondary primary tumors. The secondary outcomes are the incidence of colorectal adenomatous polyps greater than 1cm, incidence of high-grade colorectal polyps, treatment-related adverse events, disease-free Survival and overall Survival.

There are two groups: the PD-1 antibody prevention group and the routine follow-up group. For the PD-1 antibody prevention group, participants will receive Toripalimab 240mg IV every 3 months for a year. For the routine follow-up group, there is no drug intervention.

This whole study will take 5 years: the first year for recruiting and the latter four years for follow-up.

Condition Colorectal Cancer, Colorectal Cancer, Colon Cancer Screening, Colon cancer; rectal cancer, Lynch Syndrome, Hereditary Neoplastic Syndrome, Hereditary Cancer Syndromes, Colon Cancer Screening, Colon cancer; rectal cancer, Hereditary Cancer Syndromes, hnpcc
Treatment PD-1 antibody
Clinical Study IdentifierNCT04711434
SponsorSun Yat-sen University
Last Modified on29 January 2021


Yes No Not Sure

Inclusion Criteria

Lynch syndrome with germline variants of MLH1, MSH2, or EPCAM (pathogenic or likely pathogenic variants)
Necessary treatments have been done, such as surgery, chemotherapy, radiation therapy, etc
Have a resection, including right hemicolectomy, left hemicolectomy, sigmoid colectomy, or anterior resection of rectal cancer, or endoscopic adenoma resection
Aged 18-70 years old
Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
White blood cell (WBC) > 4000/mm3, Platelet count >100000/mm3, HB >10 g/dL
Serum glutamic-oxaloacetic transaminase (SGOT) < 1.5 the upper limit of normal (ULN), Serum glutamic pyruvic transaminase (SGPT) < 1.5 ULN prior to randomization, Total bilirubin (TBIL) < 1.5 mg/dL
Serum creatinine (Scr) <1.8 mg/dL

Exclusion Criteria

Lynch syndrome with germline variants of MSH6 and PMS2
Previous immunotherapy has been taken, such as anti-PD-1, anti-PD-L1, etc
Long-term use of aspirin
Suffering from autoimmune diseases
Active infection with hepatitis B or hepatitis C (high copy number of viral DNA) or human immunodeficiency virus (HIV)
Other clinically serious active infections (NCI-CTC 4.0)
With cachexia or organ dysfunction
Suffering from seizures requiring treatment (such as steroids or antiepileptic therapy)
Unable to participate or complete the study due to substance abuse, or medical, psychological, or social disorder
Known allergy to any drugs in this study
Pregnant or nursing women, or women of childbearing potential who are not using adequate contraception
Any unstable condition or situation that could compromise the safety and compliance of participants
Failure to sign an informed consent form
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note